Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31392754 | 1.00 | CES2 (0.50) | CES2CES1TSHRCASP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9860906 | 0.98 | CES2 (0.48) | CES2CES1TSHRCASP1SMN1; SMN2 | |
| SCHEMBL109128 | 0.84 | TSHR (0.48) | CES2CES1TSHRCASP1SMN1; SMN2 | |
| SCHEMBL9860898 | 0.83 | CES2 (0.50) | CES2CES1TSHRCASP1SMN1; SMN2 | |
| SCHEMBL7749586 | 0.83 | CES2 (0.50) | CES2CES1TSHRCASP1SMN1; SMN2 | |
| SCHEMBL29488311 | 0.83 | TSHR (0.47) | CES2CES1TSHRCASP1SMN1; SMN2 | |
| SCHEMBL364951 | 0.83 | TSHR (0.47) | CES2CES1TSHRCASP1SMN1; SMN2 | |
| SCHEMBL107955 | 0.83 | TSHR (0.52) | TSHRCASP1SMN1; SMN2MAP2K1KEAP1 | |
| SCHEMBL28580395 | 0.81 | TSHR (0.50) | TSHRCASP1SMN1; SMN2MAP2K1KEAP1 | |
| SCHEMBL2581821 | 0.81 | CES2 (0.48) | CES2CES1CASP1MAP2K1MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054187-A1 | TGR5 ANTAGONISTS AND METHODS OF USE | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-03-13 | — | — | WO | disclosed |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (US) | 2022-11-03 | — | — | US | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3863711-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| CN-113195053-A | Amino acid compounds and methods of use | 普利安特治疗公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210220356-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-22 | — | — | US | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| US-20100056595-A1 | Pyrazole Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2150535-A2 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-02-10 | — | — | EP | disclosed |
| WO-2009074518-A1 | COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009053459-A1 | 4-BENZ0YL-1-SUBSTITUTED-PIPERAZIN-2-0NE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
| EP-2049478-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | Glaxo Group Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008125600-A2 | PYRAZOLE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-23 | — | — | WO | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| WO-2008003697-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | CES2 4227/4885CES1 1077/4885TSHR 2320/4885 |
| US-20210220356-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, TYMP, HAVCR2 | CES2 4342/4885CES1 1945/4885TSHR 4093/4885 |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | CES2 4094/4885CES1 1572/4885TSHR 3743/4885 |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | CES2 3816/4885CES1 2950/4885TSHR 1498/4885 |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | CES2 4241/4885CES1 1062/4885TSHR 3551/4885 |
| US-11952376-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | CES2 4411/4885CES1 1134/4885TSHR 2567/4885 |
| US-20100056595-A1 | Pyrazole Derivatives as P2X7 Modulators | P2RX3, P2RX6, P2RX7 | CES2 3039/4885CES1 2110/4885TSHR 713/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | CES2 4411/4885CES1 1134/4885TSHR 2567/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | CES2 2000/4885CES1 206/4885TSHR 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.